Association of Multiple Dopamine D3 Receptor Gene 3'UTR Polymorphisms with Susceptibility to Parkinson's Disease and Clinical Efficacy of Piribedil Therapy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): Zhang R;Zhang R; Li J; Li J; Wu Y; Wu Y; Liang S; Liang S; Xu L; Xu L
  • Source:
    Genetic testing and molecular biomarkers [Genet Test Mol Biomarkers] 2021 Jan; Vol. 25 (1), pp. 20-30. Date of Electronic Publication: 2020 Dec 28.
  • Publication Type:
    Clinical Trial; Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 101494210 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1945-0257 (Electronic) Linking ISSN: 19450257 NLM ISO Abbreviation: Genet Test Mol Biomarkers Subsets: MEDLINE
    • Publication Information:
      Original Publication: New Rochelle, NY : Mary Ann Liebert, Inc.
    • Subject Terms:
    • Abstract:
      Objective: To investigate the correlation between the Dopamine D3 receptor ( DRD3 ) 3'untranslated region (3'UTR) gene polymorphism and susceptibility to Parkinson's disease (PD) and the clinical effect of the DRD2 and DRD3 agonist piribedil treatment. Methods: Sanger sequencing was used to analyze the single nucleotide polymorphisms (SNPs) within the 3'UTR rs76126170, rs9868039, rs9817063, and rs3732790 loci of the DRD3 gene in 284 PD patients and 284 controls. PD patients were treated with piribedil sustained-release tablets (50 mg) combined with levodopa and benserazide hydrochloride tablets , three times daily (patients with first-diagnosed PD were only administrated with piribedil sustained-release tablets) for 3 months. The Unified Parkinson's Disease Rating Scale (UPDRS) and the Hoehn and Yahr disease stage were evaluated at baseline and after 3 months of treatment. Results: The T allele carriers of the DRD3 gene rs76126170 locus were more susceptible to PD than the C allele carriers (odds ratio [OR] = 3.44, 95% confidence interval [CI]: 2.46-4.80, p  < 0.01). Carriers of the rs9868039 A allele had a decreased risk of PD compared to those with G allele (OR = 0.67, 95% CI: 0.53-0.86, p  < 0.01). C allele carriers at rs9817063 were less likely to develop PD than those with T allele (OR = 0.74, 95% CI: 0.58-0.94, p  = 0.02). No significant correlation was observed between the alleles or genotypes of the rs3732790 locus and PD susceptibility ( p  > 0.05). The various genotypes of the DRD3 gene loci rs76126170, rs9868039, and rs9817063 in PD patients were associated with significant differences with regard to reduction of UPDRS scores and Hoehn and Yahr stage after 3 months of treatment ( p  < 0.05). Conclusion: The alleles and genotypes of the DRD3 gene 3' UTR SNP loci rs76126170, rs9868039, and rs9817063 are associated with PD susceptibility and the clinical efficacy of piribedil treatment.
    • Contributed Indexing:
      Keywords: Parkinson's disease; dopamine D3 receptor; piribedil; single nucleotide polymorphism
    • Accession Number:
      0 (3' Untranslated Regions)
      0 (DRD3 protein, human)
      0 (Receptors, Dopamine D3)
      DO22K1PRDJ (Piribedil)
    • Publication Date:
      Date Created: 20201229 Date Completed: 20210128 Latest Revision: 20210128
    • Publication Date:
      20240105
    • Accession Number:
      10.1089/gtmb.2020.0195
    • Accession Number:
      33372861